Short Courses and Special Courses

SC19 - Melanocytic Lesions: A Practical Approach to Diagnosis, Adjunctive Molecular and Appropriate Therapy/Management

Thursday, March 22, 2018 - 8:00 am - 11:30 am
This Short Course session includes up to a half-hour break.

Session Credits:

3 CME and 3 SAMs


Martin C. Mihm, Jr. MD, Brigham & Women’s Hospital, Boston, MA
Richard A Scolyer, MD, Royal Prince Alfred Hospital, Sydney, Australia
Adriano Piris, MD, Brigham and Women’s Hospital, Boston, MA

Course Description

Melanocytic tumors are a frequent source of diagnostic difficulty for practicing Surgical Pathologists, Dermatopathologists and General Pathologists. To prepare this course, a systematic process for addressing education/training needs for this group of practitioners was undertaken by analysis of departmental Quality Assurance reports and extensive consultation cases. This course was developed to address gaps of knowledge in specific fields of the discipline including not only in diagnostic approaches but also molecular genetics applied to diagnosis and predictive and prognostic biomarkers and their impact on therapy. A case-based format will be utilized to illustrate these various issues. Each case will be discussed with emphasis on the approach to histopathological diagnosis, immunohistochemistry and molecular techniques and their pitfalls will be highlighted. Active learning will be promoted by enhancing participant’s self-belief that they can learn, increasing their confidence and commitment to learning. Using virtual slides, participants will be enabled to work autonomously prior to the meeting.

Learning Objectives

Upon completion of this educational activity, the learner will be able to:

  • Accurately diagnosis a selection of challenging melanocytic lesions
  • Appropriately apply ancillary IHC and molecular-based studies to challenging cases and avoid pitfalls in their interpretation
  • Understand the role of the pathologist in guiding the appropriate therapy for melanoma patients (immunotherapy, specific targeted therapy or combination therapy)
  • Be more aware of the changing significance of important immunohistochemical stains as diagnostic and predictive biomarkers.


Continuing Medical Education and Maintenance of Certification

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 3 SAM credit hours.


Return to 2018 Annual Meeting Short Course Page


view more